ライフサイエンスコーパス: before the index date

1 Before the index date, 22% of HF cases and 23% of controls ha

2 zation, use of nonopioid medications, and opioid use on and before the index date.

3 zodiazepine use, as well as other covariates, were assessed before the index date (which was either the date of hospital

4 Sixty-two (38%) of the 164 cases had asthma before the index date of pertussis compared with 85 (26%) of

5 The mean age at diagnosis of the first cancer before the index date was similar in the cases (67.5 +/- 11.9

6 otal of 5184 of sample patients (5.1%) had a migraine claim before the index date; 1215 (6.1%) among cases and 3969 (4.9%

7 ording (i.e., index date), and years of history in the CPRD before the index date.

8 VASc score was assessed using electronic health record data before the index date.

9 ols had an acute respiratory-tract infection in the 10 days before the index date (54 [2.8%] vs 72 [0.9%]).

10 tion to an acute respiratory-tract infection in the 10 days before the index date.

11 the index date and use of brain imaging during the 180 days before the index date were collected.

12 respiratory-tract infection 1-5, 6-10, 11-15, or 16-30 days before the index date (compared with participants who had no

13 Use of PPIs within 30 days before the index date.

14 th no prescription for an a1-blocker filled within 365 days before the index date) and those currently receiving 5a-reduc

15 years) with at least 1 baseline visit (24 months to 7 days before the index date) and at least 1 follow-up visit (28 to

16 PPI usage up to 90 days before the index date remained statistically significant.

17 f cases who had an acute respiratory-tract infection either before the index date or before an arbitrarily chosen date (1

18 and had at least 1 year of continuous insurance enrollment before the index date.

19 o matter whether the patients had prior severe exacerbation before the index date, those receiving angiotensin-converting

20 d controls the date of the last respiratory-tract infection before the index date was identified.

21 r AD risk increased with a VPI exposure of 100 days or less before the index date (aOR, 2.10; 95% CI, 1.40-3.15), mainly

22 as only significant among patients with injury in the month before the index date.

23 prescribed new antihypertensive treatment in the 12 months before the index date (baseline).

24 ls (34.5%) received at least 1 vaccine within the 12 months before the index date.

25 Propensity score matching was used at baseline (12 months before the index date: first OCS use).

26 Invasive dental procedures within 6 months before the index date was observed in 21 of 362 (6%) patients

27 23.5 hours, and >23.5 hours) was assessed over the 6 months before the index date.

28 index date), database encounter activity (6 months or more before the index date), and no evidence of HIV, hepatitis C o

29 tario Health Insurance Plan number or a date of death on or before the index date.

30 apart, >=6 months of continuous enrollment in a health plan before the index date, and >=18 months of continuous enrollme

31 s apart, 6 months of continuous enrollment in a health plan before the index date, and 18 months of continuous enrollment

32 nital toxoplasmosis, having < 2 years in the insurance plan before the index date, and without >= 1 visit to an eyecare p

33 Exclusion of antiepileptic drugs prescribed before the index date did not meaningfully alter the findings

34 e index date, and without >= 1 visit to an eyecare provider before the index date were excluded from the study.

35 birth, sex, general practice, and years of medical records before the index date.

36 ctice site and both duration and calendar time of follow-up before the index date.

37 th calendar period and duration of up-to-standard follow-up before the index date.

38 current and recent use of antipsychotic drugs with non-use before the index date in cases and controls.

39 reatest percentage increase in mean (SEM) z-scores after vs before the index date (298.0% [57.0%]; P < .001), followed by

40 d drugs within 30 days (current use) and other time windows before the index date.

41 Within 1 year before the index date, 68% of cases and 52% of controls used

42 in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded.

43 and histamine 2-receptor antagonists (H2RA) during the year before the index date were identified.

44 sO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019,

45 nd (for the inpatient care analysis) hospital days the year before the index date.

46 Conditions significantly associated with LCINS 1-10 years before the index date were validated in an independent datase

47 (CIs) of dementia associated with common vaccines >2 years before the index date compared with no exposure during the st

48 y, where prescriptions were counted from 1995 until 2 years before the index date, there was a slightly higher odds ratio

49 However, use of penicillins in the 3 years before the index date decreased the risk of developing a firs

50 s had used menopausal hormone therapy more than three years before the index date.